تداخلات ديسلفيرام

WARNING Disulfiram should never be administered to a patient when he is in a state of alcohol intoxication, or without his full knowledge. (نشرة ديسلفيرام، تحذير مؤطر)

Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with TRACLEER is not recommended. (نشرة بوسنتان، التداخلات الدوائية)

CONTRAINDICATIONS Patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram. (نشرة ديسلفيرام، موانع الاستعمال)

Alcohols, Disulfiram: Alcoholic beverages and preparations containing ethanol or propylene glycol should be avoided during tinidazole therapy and for 3 days afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur. (نشرة تينيدازول، التداخلات الدوائية)

…reactions to dronabinol include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing, throat tightness [see Adverse Reactions ( 6.2 )] . with a history of a hypersensitivity reaction to alcohol. who are receiving, or have recently received, disulfiram- or metronidazole-containing products within 14 days [see Warning and Precautions ( 5.3 )] . (نشرة درونابينول، موانع الاستعمال)

Avoid using NUMBRINO in patients taking disulfiram. (نشرة كوكايين، التداخلات الدوائية)

Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (نشرة ماسيتنتان، التداخلات الدوائية)

CONTRAINDICATIONS Patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram. (نشرة ديسلفيرام، موانع الاستعمال)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (نشرة ديسلفيرام، التداخلات الدوائية)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (نشرة ديسلفيرام، التداخلات الدوائية)

HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (نشرة أفانافيل، التداخلات الدوائية)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (نشرة إليكساكافتور وتيزاكافتور وإيفاكافتور، التداخلات الدوائية)

Disulfiram Decreases theophylline clearance by inhibiting hydroxylation and demethylation. (نشرة أمينوفيلين، التداخلات الدوائية)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (نشرة ديسلفيرام، التداخلات الدوائية)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (نشرة ديسلفيرام، التداخلات الدوائية)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (نشرة ديسلفيرام، التداخلات الدوائية)

CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. (نشرة توراسيميد، التداخلات الدوائية)

Disulfiram Decreases theophylline clearance by inhibiting hydroxylation and demethylation. (نشرة ثيوفيلين، التداخلات الدوائية)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (نشرة ديسلفيرام، التداخلات الدوائية)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co- administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac. (نشرة ديكلوفيناك، التداخلات الدوائية)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g., voriconazole) may enhance the exposure and toxicity of diclofenac [see Clinical Pharmacology (12.3) ] whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of diclofenac. (نشرة ديكلوفيناك وميزوبروستول، التداخلات الدوائية)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (نشرة راميلتيون، التداخلات الدوائية)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (نشرة روسوفاستاتين، التداخلات الدوائية)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (نشرة ديسلفيرام، التداخلات الدوائية)

Zafirlukast exposure is likely to be increased by other moderate and strong CYP2C9 inhibitors. (نشرة زافيرلوكاست، الاحتياطات)

Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g., fluconazole) may enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of celecoxib. (نشرة سيليكوكسيب، التداخلات الدوائية)

…(cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels… (نشرة فوسفينيتوين، التداخلات الدوائية)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (نشرة ديسلفيرام، التداخلات الدوائية)

DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS RECEIVING PHENYTOIN AND ITS CONGENERS, SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION. (نشرة ديسلفيرام، التداخلات الدوائية)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (نشرة كارفيديلول، التداخلات الدوائية)

Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. (نشرة لاكوساميد، التداخلات الدوائية)

Thus concomitant usage of CYP2C9 inhibitors (such as amiodarone, fluconazole, and sulphaphenazole) may lead to abnormally high plasma levels of meloxicam due to reduced metabolic clearance [ see Use in Specific Populations ( 8.8 ); and Clinical Pharmacology ( 12.3 , 12.5 ) ]. (نشرة ميلوكسيكام، التداخلات الدوائية)

…salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid, and inhibitors of CYP2C9 (e.g., amiodarone, fluconazole, voriconazole, sulfinpyrazone) or in patients known to be poor metabolizers of CYP2C9 substrates, alcohol. (نشرة ناتيغلينيد، التداخلات الدوائية)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (نشرة ديسلفيرام، التداخلات الدوائية)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (نشرة ديسلفيرام، التداخلات الدوائية)

Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram – see WARNINGS section. (نشرة أميتريبتيلين، التداخلات الدوائية)

Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). (نشرة أوميبرازول، التداخلات الدوائية)

Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). (نشرة أوميبرازول وبيكربونات الصوديوم، التداخلات الدوائية)

Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status, the disulfiram should be discontinued if such signs appear. (نشرة ديسلفيرام، التداخلات الدوائية)

Toremifene is a weak inhibitor of CYP2C9. (نشرة توريميفين، التداخلات الدوائية)

Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. (نشرة تيربينافين، التداخلات الدوائية)

Additionally, no disulfiram-like reactions were reported in a study conducted in 22 healthy volunteers administered cefotaxime and ethanol. (نشرة سيفوتاكسيم، التداخلات الدوائية)

The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a HIV protease inhibitor and a highly strong CYP3A4 inhibitor, which also inhibits CYP2C9. (نشرة فاردينافيل، التداخلات الدوائية)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (نشرة كلوبيدوغريل، التداخلات الدوائية)

Alcohol: Exceptional cases have been reported of a disulfiram-like reaction to alcohol, characterized by flushing, rash, peripheral edema, nausea and headache. (نشرة كيتوكونازول، التداخلات الدوائية)

Disulfiram/metronidazole KALETRA oral solution contains ethanol, which can produce disulfiram-like reactions when co-administered with disulfiram or other drugs that produce this reaction (e.g., metronidazole). (نشرة لوبينافير وريتونافير، التداخلات الدوائية)

The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (نشرة أكامبروسات، التداخلات الدوائية)